Although Alda does not compete in the same league as GlaxoSmithKline and Pfizer, earnings are up for drugmaker's dispite an econmic downturn. Maybe this is an indication that pharma stocks are a good choice during these rough times. When we start trading on the U.S. market, maybe U.S. investors will see it this way too and be interested in less expensive pharma stocks like Alda.